Volume 30, Number 10—October 2024
Dispatch
Mpox Epidemiology and Vaccine Effectiveness, England, 2023
Table 3
Doses | Cases in 2023 | Corrected cases† | PCV, % |
PPV, % | PPV, sensitivity, %‡ | VE, % (95% CI) | VE sensitivity, % (95% CI)‡ | |
---|---|---|---|---|---|---|---|---|
0 | 54 | 65.4 | 52 | 16 | 30 | |||
1 | 20 | 24.2 | 19 | 38 | 32 | 84 (74–91) | 65 (42–79) | |
2 | 30 | 36.4 | 29 | 45 | 38 | 80 (69–83) | 56 (31–72) | |
Unknown | 22 | |||||||
1 or 2 | 50 | 60.6 | 48 | 84 | 70 | 82 (74–88) | 60 (41–73) | |
Total | 126 | 126 |
*PCV, percentage of case-patients with the given number of doses; PPV, percentage of the population with the given number of doses obtained by matching each case to the population uptake 14 d before onset and averaging this across cases; VE, vaccine effectiveness. †22 case-patients with unknown vaccination status distributed among 0, 1, and 2 doses. ‡Based on the higher estimated denominator for gay, bisexual, men who have sex with men (107,088).
Page created: August 27, 2024
Page updated: September 23, 2024
Page reviewed: September 23, 2024
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.